Sabra Health Care REIT, Inc. (SBRA) Stock Price & How to Invest

Sabra Health Care REIT is a self-managed real estate investment trust that owns and invests in healthcare property, including skilled nursing and transitional care facilities, managed senior housing communities, behavioral health, and specialty hospitals, spread across the United States and Canada. Its portfolio mixes triple-net leases (where operators pay Sabra fixed rent) with managed senior housing under RIDEA-style structures that give Sabra direct exposure to the operating income of those communities, so a chunk of its results moves with occupancy and rate trends in senior living.

The investment picture centers on income and demographics. Sabra pays a quarterly dividend of $0.30 per share (about a 6.2% yield at the October 16, 2026 price of $19.41) and its results are recovering as senior housing occupancy and rates climb off pandemic lows. In the second quarter of 2026 revenue rose to about $236 million from $189 million a year earlier, beating forecasts, normalized FFO was $0.38 per share and normalized AFFO $0.40 (up 5%), and same-store managed senior housing cash NOI rose 13.7% with occupancy up 170 basis points to 88.2%. Reported net income swung to a loss of about $25 million in the quarter because of a $102.4 million provision for loan losses and other reserves, mostly tied to the discounted payoff of a mortgage loan, which is excluded from normalized results. The stock is up 1.4% in 2026 but down 11.9% over the three months to October 16. Third-quarter results are due November 4, 2026. Against that, the company carries meaningful leverage and depends on the financial health of its operators, so it trades more like a yield-plus-modest-growth vehicle than a high-growth name.

Sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection. The re-tenanting of properties (such as the Avamere-to-Cascadia transition) carries execution risk during handover. As a REIT it is sensitive to interest rates, which affect both its borrowing costs and how income investors value its yield. Leverage remains meaningful for a healthcare landlord, and the dividend, while covered by cash flow today, depends on continued occupancy recovery. Competition from far larger peers for acquisitions can compress the yields Sabra earns on new deals. The second-quarter 2026 provision of $102.4 million for loan losses, tied to the discounted payoff of a mortgage loan, is a reminder that Sabra's lending and leasing exposure to operators can produce sizable write-downs. Reliance on forward equity sales to fund acquisitions also dilutes existing holders, and GAAP payout ratios look stretched (the trailing dividend is several times GAAP earnings) even though the normalized AFFO payout is about 75%.

14 analysts publish price targets on SBRA, averaging $22.50 against a $19.34 price as of October 2026, or +16.3%. The published targets run from $19.00 to $25.00, a narrow spread, and the ratings split 6 buy, 10 hold, 0 sell. Over the last six months there have been 6 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SBRA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Sabra Health Care REIT, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Senior housing operating recovery. Sabra's managed senior housing portfolio is the main growth engine, with same-store cash NOI up 13.7% year over year in the second quarter of 2026 (after roughly 14% in the first), occupancy up 170 basis points to 88.2%, and revenue per occupied unit up 6.6%. The most optimistic published target, $25.00, assumes this works close to its best case.

The case against. Sabra depends heavily on the financial health of its tenant operators, and skilled nursing operators in particular run on thin margins tied to Medicare and Medicaid reimbursement, so rate changes or operator distress can pressure rent collection. The most pessimistic target, $19.00, is roughly what SBRA is worth if this bites instead.

Read the full bull and bear case on SBRA, including what would have to change to break either one. Walnut is not an investment adviser.

No. Sabra Health Care REIT, Inc. (SBRA) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Sabra Health Care REIT, Inc.'s investor relations page or your broker.

• Market cap: ~$5.0B
• Revenue (TTM): ~$864M (+25% y/y in Q2 2026)
• Normalized AFFO/share (Q2 2026): $0.40 (+5% y/y)
• Normalized FFO/share (Q2 2026): $0.38
• Net income (TTM): ~$65M, after a ~$102M Q2 loan-loss provision
• Dividend yield: ~6.2% ($1.20 annual)
• Net debt / adjusted EBITDA: ~4.6x (June 30, 2026)

At $19.41 on October 16, 2026, the shares trade at roughly 12 times annualized second-quarter normalized AFFO and about 1.8 times book value; GAAP P/E figures (about 78 trailing) are distorted by depreciation and the second-quarter reserve and say little about a REIT. The $0.30 quarterly dividend is about 75% of normalized AFFO, leaving some cushion. Third-quarter results on November 4, 2026 will show whether same-store senior housing NOI growth stays in the low-to-mid teens and how quickly the new acquisitions add to AFFO.

Other names that sit close to SBRA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get SBRA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SBRA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SBRA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

SBRA is an income-oriented, aging-demographics healthcare REIT whose story turns on senior housing recovery and tenant credit quality, so the yield comes packaged with operator and interest-rate risk. The second quarter of 2026 kept the recovery story intact, with normalized AFFO of $0.40 per share and same-store managed senior housing NOI up 13.7%, even as a loan-loss reserve pushed reported net income into a loss.

Whether SBRA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SBRA a buy or a sell?, and where the stock could go from here in the SBRA stock forecast.

For income investors, whether SBRA pays a dividend and how the payout looks is covered in does SBRA pay a dividend? And to weigh SBRA against a peer, read the full side-by-side comparisons: SBRA vs WELL and SBRA vs VTR.